News

REGENXBIO Set to Showcase Innovations at Major Healthcare Gathering

REGENXBIO Set to Showcase Innovations at Major Healthcare Gathering

REGENXBIO to Present at a Key Healthcare Event

REGENXBIO Inc. (Nasdaq: RGNX) has announced its upcoming presentation at a prominent healthcare conference. This annual event is known for bringing together key stakeholders in the healthcare and biotechnology sectors.

Presentation Highlights

The exciting presentation is scheduled for 10:30 a.m. PT on a Wednesday in early January 2026. The venue for this important gathering will be the Westin St. Francis in a major city known for its influence in healthcare innovation.

Webcast Availability

For those unable to attend in person, REGENXBIO will provide a live webcast of the presentation, which can be found in the Investors section of the company's official website. An archived version of the webcast will also be available for about a month following the live event, allowing investors and stakeholders to catch up on the insights shared.

About REGENXBIO Inc.

Founded in 2009, REGENXBIO is a trailblazer in the biotechnology sector, focusing on harnessing the curative potential of gene therapy. The company has made significant strides in the realm of adeno-associated virus (AAV) gene therapy, positioning itself as a leader in the development of one-time medical solutions for rare and retinal diseases.

Innovative Treatments in Development

REGENXBIO's commitment to innovation is evident in its advanced pipeline of therapeutic candidates. Among the noteworthy advancements are RGX-202, aimed at treating Duchenne muscular dystrophy, and two therapies in collaboration with Nippon Shinyaku: clemidsogene lanparvovec (RGX-121) for MPS II and RGX-111 for MPS I. Another exciting development is surabgene lomparvovec (ABBV-RGX-314), intended for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy, created in partnership with AbbVie.

Impact on Patient Care

To date, thousands of patients have benefitted from treatments utilizing REGENXBIO's AAV platform, which includes recognition for treatments such as Novartis' ZOLGENSMA®. The therapeutic solutions being developed have the potential to transform healthcare delivery and improve the quality of life for millions of individuals facing rare diseases.

Keeping in Touch

The company encourages stakeholders and the public to stay updated on their advancements and presentations by visiting their official website, where more information can be found about their ongoing projects and the latest news in gene therapy applications.

Frequently Asked Questions

What is the purpose of REGENXBIO's presentation?

REGENXBIO's presentation aims to showcase their advancements in gene therapy and share insights about their innovative treatments in the pipeline.

When will the presentation take place?

The presentation is set for 10:30 a.m. PT on a Wednesday in early January 2026.

Where can I access the webcast of the presentation?

A live and archived webcast of the presentation will be available in the Investors section of REGENXBIO's official website.

What are some of the key treatments being developed by REGENXBIO?

REGENXBIO is developing several innovative treatments, including RGX-202 for Duchenne muscular dystrophy and RGX-121 and RGX-111 for MPS II and MPS I respectively.

How has REGENXBIO impacted patient care?

Through its AAV platform, REGENXBIO has treated thousands of patients and continues to work towards curative therapies that improve the lives of individuals with rare diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 33

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 15

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 28

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 26

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 34

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 32

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 23

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading

Top 5 Most Recently Viewed Articles

Global Supply Chains Report 2025: Key Insights for Business Growth

Updated Category News Views 251

Introduction to the Global Supply Chains Report 2025 Supply Chain Digital, a prominent brand under BizClik, has recently unveiled its highly anticipated annual report, the Global Supply Chains Report 2025. This report aims to shed light on the organizations that are reshaping the landscape of global supply chains through innovation, sustainability, and resilience....

Continue Reading
Absci's Innovative Drug Pipeline and AI Breakthroughs Unveiled

Updated Category News Views 410

Innovative Developments at Absci's R&D Day Absci Corporation, renowned for its pioneering approach in drug creation using generative AI, recently highlighted its progress during a significant event focused on research and development. The company showcased its proprietary Drug Creation pipeline and advancements achieved through the AI Integrated Drug Creation™ platform....

Continue Reading
Exciting Developments in JAKKS Pacific's Financial Journey

Updated Category News Views 84

JAKKS Pacific to Announce Fourth Quarter and Year-End Results JAKKS Pacific, Inc. (NASDAQ: JAKK) is gearing up to share its financial performance for the fourth quarter and full year. The eagerly anticipated announcement will be made following the market close, drawing attention from analysts, investors, and the media alike. This event signifies not only the conclusion of...

Continue Reading
Crowley Enhances Logistics for Wreaths Across America Initiative

Updated Category News Views 153

Crowley Enhances Logistics for Wreaths Across America Initiative Crowley is taking significant steps to expand its logistical support for the Wreaths Across America program, reflecting its strong commitment to honoring U.S. military personnel. The company is facilitating this through financial sponsorship along with in-kind transportation and logistics services. Expanded...

Continue Reading
Unlocking the Wealth from Shopify: 15 Years of Growth Insights

Updated Category News Views 290

Shopify's Impressive Market Performance Over the past 15 years, Shopify (NASDAQ: SHOP) has consistently outperformed the market, boasting an impressive annualized return of 23.52%. This remarkable growth translates to a significant increase in wealth for those who invested in the company early on. At present, Shopify holds a market capitalization of $153.87 billion,...

Continue Reading